IP Library › Granted Patent US 10,149,886
Granted Patent B2
US 10,149,886 · App. 15/286,491 · Granted Dec 11, 2018

Peptides having anti-inflammatory properties

Inventors: Jesse Jaynes (Auburn, AL); Henry Wilfred Lopez (Napa, CA); George R. Martin (Rockville, MD); Clayton Yates (Auburn, AL); Charles Garvin (Redwood City, CA)
Assignee: Riptide Bioscience, Inc.
A61K38/08A61K31/282A61K31/337A61K31/4745A61K31/513A61K31/519A61K31/7068A61K36/10A61K38/04A61K38/10A61K38/16A61K45/06C07K5/08C07K5/10C07K7/06C07K7/08C07K14/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,149,886
App. No.
15/286,491
Granted
Dec 11, 2018
Kind
B2
Abstract

Aspects of the present invention relate to peptides having anti-inflammatory activity, compositions containing one or more of the peptides, and use of the peptides to treat conditions associated with excessive inflammation in animals, particularly humans and other mammals.

Claims (14)

1. An immunomodulatory peptide of 18 amino acid residues or less in length, wherein the peptide has a sequence defined by one of the formulae:

[Y 1a Y 1b ]-[X 1a X 1b ]-[Y 2a Y 2b ]-[X 2a X 2b ]-[Y 3a ]-[X 3a ]; and

[X 3a ]-[Y 3a ]-[X 2b X 2a ]-[Y 2b Y 2a ]-[X 1b X 1a ]-[Y 1b Y 1a ];

wherein:

Y 1a , Y 1b , Y 2a , Y 2b and Y 3a are each phenylalanine; and

X 1a , X 1b , X 2a , X 2b and X 3a are each independently selected from lysine and arginine.

2. The immunomodulatory peptide according to claim 1 , wherein the striapathic region of the peptide has a length of 12 amino acid residues or less.

3. The immunomodulatory peptide according to claim 1 , wherein the peptide comprises the amino acid sequence FFKKFFKKFK (SEQ ID NO:123).

4. The immunomodulatory peptide according to claim 2 , wherein the peptide consists essentially of the amino acid sequence FFKKFFKKFK (SEQ ID NO:123).

5. The immunomodulatory peptide according to claim 1 , wherein the peptide comprises the amino acid sequence KFKKFFKKFF (SEQ ID NO:124).

6. The immunomodulatory peptide according to claim 2 , wherein the peptide consists essentially of the amino acid sequence KFKKFFKKFF (SEQ ID NO:124).

7. An immunomodulatory peptide of 18 amino acid residues or less in length, the peptide comprising the amino acid sequence KFKKAFKKAF (SEQ ID NO:148) or FFRKFAKRFK (SEQ ID NO:122).

8. The immunomodulatory peptide according to claim 7 , wherein the peptide consists essentially of the amino acid sequence KFKKAFKKAF (SEQ ID NO:148).

9. The immunomodulatory peptide according to claim 7 , wherein the peptide consists essentially of the amino acid sequence FFRKFAKRFK (SEQ ID NO:122).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2016
From: JAYNES, JESSE; LOPEZ, HENRY WILFRED; MARTIN, GEORGE R.; YATES, CLAYTON; GARVIN, CHARLES
To: RIPTIDE BIOSCIENCE, INC.
Reel/Frame 040267/0346 →
Continuity (3)
Continuation 14882293 · Oct 13, 2015
Provisional Application 62063909 · Oct 14, 2014
Related Publication 20170020956A1 · Jan 26, 2017